Core Viewpoint - Senseonics Holdings, Inc. has received CE Mark approval for its Eversense 365 continuous glucose monitoring (CGM) system, expanding its market reach in Europe and targeting over 30 million diabetes patients [2][3]. Group 1: Product Overview - Eversense 365 is the world's first and only one-year CGM, approved by the US FDA in September 2024 and launched in October 2024 [2]. - The system is designed to provide continuous glucose monitoring for up to 365 days, significantly reducing the need for frequent sensor changes compared to traditional CGMs [6][8]. - Eversense 365 has been cleared as an integrated CGM (iCGM) system in the US, allowing it to work with compatible medical devices, including insulin pumps [4]. Group 2: Market Expansion - The approval of Eversense 365 in the EU is expected to contribute to top-line revenue growth as the company takes full ownership of all commercial activities for the product [3]. - The company plans to launch Eversense 365 in Germany, Italy, Spain, and Sweden in the coming months [2]. Group 3: Strategic Goals - The CEO of Senseonics highlighted that 2026 will be a pivotal year for the company, focusing on commercial progress in both the US and Europe, and the integration with Sequel's twiist™ Automated Insulin Delivery System [3]. - The expansion into the European market is part of a long-term growth strategy aimed at increasing the total addressable market for the company [3]. Group 4: Product Benefits - Eversense 365 offers several advantages, including reduced data interruptions, minimal sensor replacements, and improved comfort for users [6][7]. - The system provides reliable alerts and exceptional accuracy, enhancing the user experience and quality of life for diabetes patients [6][7].

Core Insights - Senseonics Holdings, Inc. received FDA approval for the Eversense 365 Continuous Glucose Monitoring (CGM) system and launched it in partnership with Ascensia Diabetes Care, marking a significant advancement in diabetes care [1][3] - The patient base for Eversense increased by 56% in 2024 compared to 2023, reaching approximately 6,000 global patients [1][6] - The company reported total revenue of $8.3 million for Q4 2024, a slight increase from $8.0 million in Q4 2023, with U.S. revenue remaining stable at $6.2 million [4] Financial Performance - Fourth quarter 2024 gross profit was $4.0 million, up from $1.1 million in Q4 2023, primarily due to improved margins on the Eversense 365 product [5] - For the full year 2024, total revenue was $22.5 million, slightly up from $22.4 million in 2023, with U.S. revenue increasing to $15.3 million from $14.1 million [9] - The net loss for Q4 2024 was $15.5 million, a reduction from a net loss of $17.2 million in Q4 2023, attributed to improved gross profit margins [8] Operational Highlights - The Eversense 365 system was launched in the U.S. in 2024, and early performance indicators showed positive results, including record new patient shipments of approximately 600 in December [6] - The company exceeded 2,400 annual U.S. prescribers for Eversense in 2024, with 81% of patients switching from competitive CGMs [6] - Senseonics initiated a collaboration with Mercy Health to study the use of Eversense and remote patient monitoring [6] Future Outlook - For 2025, Senseonics expects global net revenue to be approximately $34-38 million, anticipating a doubling of the global patient base [15] - The company plans to enhance gross margins throughout 2025, projecting margins between 25-30% for the year [15] - Cash utilization in 2025 is expected to be between $50-$60 million as the company continues to roll out Eversense 365 [15]